03/12/2025
Librela: Nebenwirkungen, wie Bänder-, Sehnen- und Gelenkschäden treten 9x häufiger auf als bei anderen Schmerzmitteln, wie Onsior, Metacam, Previcox.. Ich persönlich rate dringend von Librela ab. Es gibt genügend Alternativen, deren Auswirkungen/Nebenwirkungen besser eingeschätzt werden können.
Researchers recently conducted a specialist-led disproportionality analysis of musculoskeletal adverse event reports (MSAERs) in dogs treated with bedinvetmab (Librela™) compared to six comparator drugs with the same indication. They also reported the findings from a subset of dogs whose adverse event (AE) data underwent independent adjudication by an expert panel. The European Medicines Agency’s EudraVigilance database (2004–2024) and 19 client-owned dogs made up the sample population in the case–control study and case series analysis. An EBVS® Veterinary Specialist in Surgery individually reviewed all MSAERs to Librela™, Rimadyl®, Metacam®, Previcox®, Onsior®, Galliprant®, and Daxocox® (2004–2024). The primary null hypothesis was that Librela’s MSAER rate would not exceed that of comparator drugs by more than 50%. The secondary hypothesis was that MSAER would surge and taper following the launch of new drugs. The results showed the disproportionality analysis did not support the hypotheses. Ligament/tendon injury, polyarthritis, fracture, musculoskeletal neoplasia, and septic arthritis were reported 9-times more frequently in Librela-treated dogs than the combined total of dogs treated with the comparator drugs. A review of 19 suspected musculoskeletal adverse events (MSAEs) by an 18-member expert panel unanimously concluded a strong suspicion of a causal association between bedinvetmab and accelerated joint destruction. This study supports recent FDA analyses by demonstrating an increased reporting rate of musculoskeletal adverse events in dogs treated with Librela. Further investigation and close clinical monitoring of treated dogs are warranted.
